生命科学资讯

10x Genomics (NASDAQ:TXG) Given New $20.00 Price Target at Canaccord Genuity Group - MarketBeat

Boehringer taps Rectify to create pills for chronic kidney disease

Biopharma CEO optimism is wavering in the U.S.

Laekna Pharmaceutical divulges new PI3Kα inhibitors

Aché Laboratórios Farmacêuticos describes new SGLT-1, SGLT-2 and DPP4 inhibitors

New TEAD inhibitors disclosed in Signet Therapeutics patent

Jiangsu Simcere Biologics discovers new bispecific ADCs

Illumina (ILMN) Surges 3.3%: Is This an Indication of Further Gains? - Nasdaq

AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer

AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor

AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism

Wasatch Biolabs announces co-marketing agreement with Agilent to advance native-read targeted sequencing - News-Medical

AGILENT TECHNOLOGIES, INC. SEC 10-K Report - TradingView — Track All Markets

Agilent Technologies : Annual Report for Fiscal Year Ending October 31, 2025 (Form 10-K) - marketscreener.com

Osaic Holdings Inc. Has $8.02 Million Stock Position in Agilent Technologies, Inc. $A - MarketBeat

Aktis Oncology files for IPO to fund Lilly-partnered radiopharma pipeline

CCLA Investment Management Sells 16,843 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat

Roche Lunsumio VELO bags USFDA approval for subcutaneous use in follicular lymphoma - Medical Dialogues

Whole genome sequencing of hepatitis A virus: adapting Illumina protocols for foodborne investigation - Nature

Is There Now An Opportunity In Lonza Group AG (VTX:LONN)? - simplywall.st